3SBio takes majority stake in CP Guojian

3SBio Inc. (HKSE:1530) acquired a majority stake in biosimilar company Shanghai CP Guojian Pharmaceutical Co. Ltd. (Shanghai, China). 3SBio paid RMB1.4 billion ($213.3 million) to raise its stake to 54%. 3SBio had acquired a 7% stake in CP Guojian last year (see BioCentury, March 2).

According to a regulatory filing, 3SBio acquired equity in CP Guojian from four shareholders, including a 42% stake that it bought from Xizang Hongshang Capital Equity Investment Co. Ltd. for RMB1.1 billion ($164.8 million). ...